Development Project. A Property that has been or is intended to be developed and constructed by the Company, including, without limitation, the Properties set forth on Schedule 1 attached hereto.
Development Project. Ulthera may, at its discretion, provide from time to time a written request to GTS for development activities related to the Field (the “Development Project”). Upon receipt of such a request for a Development Project, GTS shall then submit to Ulthera in a timely manner (i) a specification for each requested Development Project, (ii) an estimate of the budget required for each requested Development Project (the “Development Budget”), wherein said Development Budget is based on commercially reasonable costs and fees, (iii) the anticipated number of months required to complete the development of such Development Project (the “Development Period”), (iv) technical specifications related to the Development Project (the “Specifications”), and (v) a schedule of providing deliverables and associated compensation adjustments for late delivery (collectively, the foregoing submission being [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. the “Proposal”). The Proposal and any related agreements for Development Services shall be negotiated in good faith by the Parties.
Development Project. Scope of Development Project 1.02 Cost of Development Project
Development Project. The project to develop TechShare.Court pursuant to the Project Addendum to the TechShare Master XXX for the Development of TechShare.Court.
Development Project. 2.1 BioStar shall undertake work for the purposes of and in relation to the Development Project as set out in the Development Work Plan. The parties may vary or add to the Development Work Plan only by written agreement of both parties from time to time during the term of the Agreement. The parties agree that any variation or addition to the Development Work Plan may require an amendment to the Development Budget.
2.2 BioStar shall use commercially reasonable efforts to ensure that it has sufficient facilities and qualified Personnel to enable it to comply with its obligations under this Agreement.
2.3 BioStar shall not enter into any other contract, arrangement or understanding with any third party or parties in respect of the matters covered by the Development Project or in relation to, or in any way involving Foreground IP without Biota's prior written consent, such consent not to be unreasonably withheld.
2.4 BioStar shall maintain full and accurate data, information and records of and concerning its work in relation to the Development Project and the results of any research studies undertaken by BioStar for the purposes of the Development Project and must make such data, information and records available to Biota as and when necessary or as and when requested by Biota. Biota shall maintain full and accurate data, information and records of and concerning its work in relation to the Development Project and the results of any research studies undertaken by Biota for the purposes of the Development Project and must make such data, information and records available to BioStar as and when necessary for the purposes of FDA Clearance of the Diagnostic.
2.5 Upon the giving of reasonable advance notice by Biota, BioStar shall permit Biota and its Personnel to enter the premises of BioStar at all reasonable times for the purpose of inspecting activities relating to the Development Project.
2.6 BioStar undertakes to Biota that it shall use all reasonable efforts to keep Biota informed of, and make available under this Agreement, new ideas, opportunities, updates in technology (including in Optical Immunoassay Technology) and technologies relating to Diagnostics and shall agree to reasonable amendments to the Development Work Plan to take account of the same from time to time. Biota undertakes to BioStar that it shall use all reasonable efforts to keep BioStar informed of, and make available under this Agreement, new ideas, opportunities, updates in technologies ...
Development Project. CMI agrees to diligently conduct research and development with a view toward completing the System development and engineering work to be performed by it as more fully described on Schedule C hereto (the "CMI Tasks"). Stryker agrees to fund [*] of the cost of the CD4I Tasks, up to a maximum expenditure therefor by Stryker of [*], but subject, unless Stryker agrees otherwise in writing, to the maximum amount budgeted for each Phase of the Development Project specified in Schedule C. CMI shall keep Stryker informed at reasonable times, orally or in writing, with respect to the status of the CMI Tasks and the overall Development Project and shall provide Stryker with a written report at the conclusion of each Phase. Promptly after the delivery of each such report, CMI shall, if requested to do so by Stryker, also give an oral presentation describing in reasonable detail the results of the Development Project through the end of that Phase as defined in Schedule C to persons designated by Stryker at a "Phase-End Meeting." The Phase-End Meetings shall be held within twenty-one (21) days of the end of that phase at locations alternately determined by CMI and Stryker. Stryker shall have the right, within 45 days of the holding of each Phase-End Meeting, to cancel the Development Project without further obligation to CMI except as set forth in paragraph 16 if the results thereof are unsatisfactory to Stryker or if Stryker shall have determined not to proceed with commercialization of the Systems. Stryker's share of the expenses for each Phase as set forth above shall be paid within forty-five (45) days after receipt of an invoice therefor, which shall be issued by CMI monthly subject to the maximum ceiling for each Phase of the Development Project and shall document in reasonable detail the total expenses incurred by CMI during the month to which it relates. As part of the Development Project, Stryker shall be responsible for the performance of the tasks assigned to it in Schedule C that are necessary to permit the interface of the System with the Stryker Products (the "Stryker Tasks"). Each of Stryker and CMI agrees to use its reasonable best efforts to perform the tasks for which it is responsible within the time allotted thereto in Schedule C. In the event that the entire project is delayed by six months or more, the party responsible therefor shall be penalized -- by a one-month reduction of the Exclusivity Period (as defined in Section 4) if Stryker's failure ...
Development Project. 1.1 POLYPEPTIDE will develop a commercial scale solution phase manufacturing process which will yield Product according to the Specification contained in Annex 1 (the "Specification"). The Specification of the Product may be changed from time to time as directed by INTRABIOTICS. Significant changes to the Specification may result in cost and timing changes to the project. The parties will negotiate in good faith and make only those necessary changes of the Time Schedule and/or the Compensation payable to POLYPEPTIDE which are a direct consequence of the change in the Specification.
1.2 POLYPEPTIDE will conduct the development project in four phases and in accordance with the Time Schedule set out in the project plan (Annex 2). Each phase will have a number of milestones as described in Annex 3. [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
1.3 PHASE I; will consist of development of the strategy and the method for [ * ] of the Product, with a [ * ] process ("Process"). In the course of Phase I, POLYPEPTIDE will produce [ * ] of Product, whereof [ * ] shall be delivered to INTRABIOTICS and the remaining [ * ] shall be used by POLYPEPTIDE for [ * ]. Phase I will be completed [ * ] based on signing of this agreement on or before 3 January 1997.
Development Project. 1.1 POLYPEPTIDE will develop a commercial scale solution phase manufacturing process which will yield Product according to the Specification contained in Annex 1 (the "Specification"). The Specification of the Product may be changed from time to time as directed by INTRABIOTICS. Significant changes to the Specification may result in cost and timing changes to the project. The parties will negotiate in good faith and make only those necessary changes of the Time Schedule and/or the Compensation payable to POLYPEPTIDE which are a direct consequence of the change in the Specification.
1.2 POLYPEPTIDE will conduct the development project in four phases and in accordance with the Time Schedule set out in the project plan (Annex 2). Each phase will have a number of milestones as described in Annex 3. [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
Development Project. The acquisition and development of Development Project Land into (a) single family housing subdivisions, or (b) two to eight unit multi-family housing subdivisions, all as approved by Lender in accordance with Section 2.2 hereof.
Development Project refers to the project document, preparing by the Contractor in accordance with the Legislation requirements and containing all the necessary information on deposit development and construction.